Armstrong S, Ganote C E
Department of Pathology, East Tennessee State University, James H Quillen College of Medicine, Johnson City 37614, USA.
Cardiovasc Res. 1995 May;29(5):647-52.
The aim was to determine if in vitro ischaemic preincubation can precondition cardiomyocytes and if the responses to adenosine receptor antagonists are similar to those previously determined during "metabolic" preconditioning with glucose deprivation or adenosine agonists.
Isolated rabbit cardiomyocytes were preconditioned with 10 min of ischaemic preincubation, followed by a 30 min postincubation before the final sustained ischaemic period. The protein kinase C inhibitor calphostin C or the adenosine receptor antagonists 8-sulphophenyltheophylline (SPT), BW 1433U, and 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) were added either during the preincubation or into the final ischaemic pellet. Adenosine deaminase (10 U.ml-1) was added during ischaemic preincubation. Rates of contracture and extent of injury were determined by sequential sampling and assessment of trypan blue permeability following 85 mOsM swelling.
Myocytes were preconditioned by a 10 min in vitro ischaemic preincubation. Preincubation with 100 microM SPT or with adenosine deaminase, or addition of 200 nM calphostin C into the final ischaemic pellet did not alter rates of rigor contracture but nearly abolished protection. A significant degree of protection was maintained following ischaemic preincubation with the highly selective adenosine A1 receptor blocker DPCPX (10 microM), while the A1/A3 antagonist BW 1433U (1 microM) severely limited protection. SPT and BW 1433U added only into the final ischaemic pellet of preconditioned cells significantly blocked protection, while protection was maintained in the presence of DPCPX.
Ischaemic preconditioning of cardiomyocytes is blocked by adenosine receptor antagonists known to bind to A3 receptors but not by DPCPX which has high affinity for A1 receptors, but little affinity for A3 receptors. Maintenance of protection during the final ischaemic phase has a similar receptor specificity. Blockade of protein kinase C activity abolishes protection. Ischaemic and metabolic preconditioning in vitro appear to occur through similar pathways.
旨在确定体外缺血预孵育是否能使心肌细胞产生预处理效应,以及对腺苷受体拮抗剂的反应是否与先前在葡萄糖剥夺或腺苷激动剂“代谢”预处理期间所确定的反应相似。
将分离的兔心肌细胞进行10分钟的缺血预孵育预处理,然后在最终的持续缺血期之前进行30分钟的孵育后处理。蛋白激酶C抑制剂钙泊三醇C或腺苷受体拮抗剂8-磺苯基茶碱(SPT)、BW 1433U和1,3-二丙基-8-环戊基黄嘌呤(DPCPX)在预孵育期间或加入最终缺血沉淀物中。在缺血预孵育期间加入腺苷脱氨酶(10 U.ml-1)。在85 mOsM肿胀后,通过顺序取样和台盼蓝通透性评估来确定挛缩率和损伤程度。
心肌细胞通过10分钟的体外缺血预孵育进行预处理。用100 microM SPT或腺苷脱氨酶预孵育,或在最终缺血沉淀物中加入200 nM钙泊三醇C,均未改变强直挛缩率,但几乎消除了保护作用。用高选择性腺苷A1受体阻滞剂DPCPX(10 microM)进行缺血预孵育后,仍维持了显著程度的保护作用,而A1/A3拮抗剂BW 1433U(1 microM)则严重限制了保护作用。仅在预处理细胞的最终缺血沉淀物中加入SPT和BW 1433U可显著阻断保护作用,而在DPCPX存在的情况下仍维持保护作用。
已知与A3受体结合的腺苷受体拮抗剂可阻断心肌细胞的缺血预处理,但对A1受体具有高亲和力、对A3受体几乎没有亲和力的DPCPX则不能。在最终缺血期维持保护作用具有相似的受体特异性。蛋白激酶C活性的阻断消除了保护作用。体外缺血和代谢预处理似乎通过相似的途径发生。